BFRI

Market-moving news on Biofrontera (NASDAQ: BFRI): filings, earnings, deals and other events, from REDFILED.

Photodynamic therapy is used in dermatology to treat pre-cancerous and cancerous skin lesions.

BFRI

FDA Approves BIOFRONTERA's Ameluz for Superficial Basal Cell Carcinoma

Ameluz with the BF-RhodoLED lamp becomes the first photodynamic therapy cleared in the US to treat a skin cancer, with a launch planned from late 2026.

Ameluz gel is used with a red-light lamp to treat skin lesions in a dermatology office.

BFRI

FDA Approves BIOFRONTERA's Ameluz PDT for Superficial Basal Cell Carcinoma

Ameluz combined with the BF-RhodoLED lamp becomes the first photodynamic therapy approved in the US to treat a skin cancer, adding up to 720,000 annual cases to its market.